CDEK
← All drugs Report issue

corticorelin ovine triflutate

Trade name: acthrel

Animal productapprovedOrphan Drug FDA

Approved

May 23, 1996

Corticorelin ovine is an analogue of the naturally occurring human corticotropin-releasing hormone (hCRH) peptide. Corticorelin ovine is a potent stimulator of adrenocorticotropic hormone (ACTH) release from the anterior pituitary. ACTH stimulates cortisol production from the adrenal cortex. Corticorelin ovine was marketed under the brand name ACTHREL for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing’s syndrome. — NCATS

Clinical trial activity

16 trials · 12 clinical orgs · 1 marketing orgs

Phase 1
5
Phase 2
6
Phase 3
4
Phase 4
4

Earliest trial started Mar 1, 2004 (NCT00033293)

Timeline

1980s

  1. Nov 24, 1989

    Orphan Drug Designation

1990s

  1. May 23, 1996

    Ferring — Earliest FDA Approval

  2. May 23, 1996

    Ferring — NDA Organization

2000s

  1. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedMay 23, 1996

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)[C@@H](C)CC)C(N)=O
Mol. weight
4757.53 g/mol
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • acthrel
  • acthrel
  • acthrel
  • acthrel
  • corticoliberin human
  • corticorelin
  • corticorelin
  • corticorelin
  • corticorelin
  • corticorelin
  • corticorelin
  • corticorelin
  • corticorelin acetate
  • corticorelin acetate
  • corticorelin acetate
  • corticorelin acetate
  • corticorelin acetate
  • corticorelin human
  • corticorelin (human)
  • corticorelin (human)
  • corticorelin ovine
  • corticorelin ovine
  • corticorelin ovine triflutate
  • corticorelin ovine triflutate
  • corticorelin ovine triflutate
  • corticorelin ovine triflutate
  • corticorelin ovine triflutate
  • corticorelin ovine triflutate
  • corticorelin ovine triflutate
  • corticorelin trifluroacetate
  • corticorelin triflutate
  • corticorelin triflutate
  • corticotropin-releasing factor
  • corticotropin-releasing factor
  • corticotropin-releasing factor (human)
  • corticotropin-releasing factor (human)
  • corticotropin-releasing factor (human)
  • corticotropin-releasing factor (sheep)
  • corticotropin-releasing factor (sheep)
  • corticotropin-releasing factor (sheep hypothalamus)
  • corticotropin-releasing factor (sheep hypothalamus)
  • corticotropin-releasing hormone
  • corticotropin-releasing hormone
  • corticotropin-releasing hormone
  • corticotropin releasing hormone human
  • crf
  • crf
  • hcrf
  • hcrf
  • human corticoliberin
  • human corticotropin-releasing factor
  • human corticotropin-releasing factor
  • l-seryl-l-glutaminyl-l-α-glutamyl-l-prolyl-l-prolyl-l-isoleucyl-l-seryl-l-leucyl-l-α-aspartyl-l-leucyl-l-valyl-l-phenylalanyl-l-histidyl-l-leucyl-l-leucyl-l-arginyl-l-α-glutamyl-l-valyl-l-leucyl-l-α-glutamyl-l-methionyl-l-threonyl-l-lysyl-l-alanyl-l-α-aspartyl-l-glutaminyl-l-leucyl-l-alanyl-l-glutaminyl-l-glutaminyl-l-alanyl-l-histidyl-l-seryl-l-asparaginyl-l-arginyl-l-lysyl-l-leucyl-l-leucyl-l-α-aspartyl-l-isoleucyl-l-alaninamide
  • neu 3002
  • neu 3002
  • ovine acth releasing factor
  • ovine corticotropin-releasing factor
  • ovine corticotropin-releasing factor
  • ovine corticotropin-releasing hormone
  • ovine corticotropin-releasing hormone
  • ovine crf 41
  • ovine crf 41
  • ovine crh
  • ovine crh
  • sheep corticotropin-releasing factor
  • sheep corticotropin-releasing factor
  • sheep corticotropin-releasing factor (1-41)
  • sheep corticotropin-releasing factor (1-41)
  • xerecept
  • xerecept
  • xerecept
  • xerecept

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04569591N/AJan 8, 2021National Institute of Neurological Disorders and Stroke (NINDS)
NCT04037605Early Phase 1 (Phase 1)Jul 24, 2019Los Angeles Biomedical Research Institute
NCT03142893Phase 1May 8, 2017Los Angeles Biomedical Research Institute
NCT01373372N/ADec 1, 2014University of Kansas
NCT02736734Phase 4Oct 1, 2014Katholieke Universiteit Leuven
NCT02674256Phase 4Mar 1, 2014Katholieke Universiteit Leuven
NCT01763281Phase 4Oct 1, 2012University of Nottingham
NCT01673087Phase 4Oct 1, 2012University of Michigan
NCT01459237Early Phase 1 (Phase 1)Oct 7, 2011National Institute of Neurological Disorders and Stroke (NINDS)
NCT01369121Phase 1/Phase 2 (Phase 2)Jun 1, 2010Celtic Pharma Development Services, Northwestern University
NCT00820092Phase 1Dec 1, 2008Celtic Pharma Development Services
NCT00691522Phase 2Nov 1, 2008Celtic Pharma Development Services, PharmaNet
NCT00226668Phase 3Jan 1, 2006Barrow Neurological Institute, Celtic Pharma Development Services, Neurobiological Technologies
NCT00226655Phase 3Jul 1, 2005Barrow Neurological Institute, Celtic Pharma Development Services, Neurobiological Technologies
NCT00088166Phase 3May 1, 2004Barrow Neurological Institute, Celtic Pharma Development Services, Neurobiological Technologies
NCT00033293Phase 3Mar 1, 2004National Cancer Institute (NCI)
Showing 16 of 16 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Celtic Pharma Development ServicesFor profit6532004
Barrow Neurological InstituteAcademic/Hospital3012004
Neurobiological TechnologiesFor profit3012004
Katholieke Universiteit LeuvenAcademic/Hospital2212014
Los Angeles Biomedical Research InstituteAcademic/Hospital2212017
National Institute of Neurological Disorders and Stroke (NINDS)Government2222011
National Cancer Institute (NCI)Government1112004
Northwestern UniversityAcademic/Hospital1012010
PharmaNetFor profit1112008
University of KansasAcademic/Hospital1112014
University of MichiganAcademic/Hospital1112012
University of NottinghamAcademic/Hospital1112012
12 organizations
Page 1 / 1

Marketing (1)

OrganizationOrg typeRelationshipDate
FerringFor profitNDAMay 23, 1996